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Osteoblastic Bone Lesions Developing During Treatment
with Erlotinib Indicate Major Response in Patients with
Non-small Cell Lung Cancer
A Brief Report
Joline S. W. Lind, MBBS, MA, Pieter E. Postmus, MD, PhD, and Egbert F. Smit, MD, PhD
Background: The osteoblastic bone flare or response is the
paradoxical phenomenon of increase in the quantity and/or den-
sity of bone lesions in the presence of well-documented disease
response to treatment in other tumor sites. It results from the
rapid repair and increased osteoblastic activity in bone metasta-
ses responding to therapy and therefore represents treatment
efficacy. Nevertheless, no reliable markers can differentiate an
osteoblastic flare or response from disease progression. In non-
small cell lung cancer (NSCLC) osteoblastic bone flare or re-
sponse has been reported in only a few patients.
Methods: Pre- and posttreatment CT scans of NSCLC patients with
osteolytic bone lesions and treated with erlotinib as a single treat-
ment modality were reviewed.
Results: In 3 cases fulfilling these criteria and responding to erlo-
tinib according to RECIST criteria, an osteoblastic bone response
was found. With the increasing use of epidermal growth factor
receptor tyrosine kinase inhibitors in patients with NSCLC harbor-
ing mutations predicting a good response, the osteoblastic response
will likely be increasingly seen. Awareness of this phenomenon with
epidermal growth factor receptor tyrosine kinase inhibitors is im-
portant for physicians treating patients with NSCLC, so that it is not
misinterpreted as progressive disease resulting in premature cessa-
tion of effective therapy.
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Bone metastases are common in non-small cell lung cancer(NSCLC) at the time of diagnosis and develop in approx-
imately 30% of patients during the course of the disease.
These are usually detected based on complaints or found in
asymptomatic patients on positron emission tomography or
bone scintigraphy. The radiologic or magnetic resonance
imaging (MRI) pattern is that of osteolysis, hardly ever
osteoblastosis. When present, osteoblastic metastases have
been only reported in adenocarcinoma.1
Osteoblastic bone flare is the paradoxical phenome-
non of temporary increase in number or intensity of lesions
on bone scintigraphy in the presence of well-documented
disease response to treatment in other tumor sites. It results
from the rapid repair and increased osteoblastic activity in
a bone metastasis responding to therapy and therefore
represents treatment efficacy. Osteoblastic response is the
radiographic equivalent of osteoblastic flare and has been
defined as a definitive increase in the quantity and/or
density of lesions, whereas clinical response is well doc-
umented. These apparently new osteoblastic lesions are not
visible at baseline and detected radiographically only after
sclerotic healing reaction has occurred.
The osteoblastic bone flare/response phenomenon is
well documented in patients with prostrate and breast
cancer receiving hormonal or chemotherapy treatment.2–5
A few cases have also been reported in patients with small
cell lung cancer responding to chemotherapy.6–8 Only
clinical characteristics of the disease can differentiate an
osteoblastic flare as a response phenomenon from disease
progression. Misinterpretation of osteoblastic bone flare or
response as progressive disease may therefore lead to
premature cessation of effective therapy.
In NSCLC, osteoblastic bone flare has been reported in
only a few patients treated with chemotherapy,9 bevacizumab
plus chemotherapy,10 and gefitinib.11–13 We report, to our
knowledge, the first cases of osteoblastic bone response in
patients treated with erlotinib for NSCLC.
CASE HISTORY 1
In May 2007, a 47-year-old nonsmoking white fe-
male was diagnosed with stage IIIa (T2N2M0) adenocarci-
noma of the right upper lobe for which she received
cisplatin and etoposide with concurrent radiotherapy (56
Gy in 28 fractions) followed by a sleeve lobectomy of the
right upper lobe. In July 2008, she presented with left hip,
back, and right shoulder pain. Bone scintigraphy, com-
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puted tomography (CT), and MRI confirmed multiple os-
teolytic bone metastases in her vertebral column, left
acetabulum, sacrum bilaterally, and right acromium with
an associated pathologic fracture (Figure 1A). Because
mutational analysis of a metastasis in a mediastinal lymph
node dissected at the time of the sleeve resection demon-
strated an activating epidermal growth factor receptor
(EGFR) mutation (exon 19 deletion) predicting a good
response, she commenced erlotinib 150 mg once daily and
received palliative radiotherapy (8 Gy in 1 fraction) to her
lower lumbar vertebrae and sacrum. Her symptoms im-
proved, and a follow-up CT scan of the thorax after 3
months demonstrated increased osteosclerosis at the site of
the metastasis in the right acromium, with the pathologic
fracture no longer visible (Figure 1B). The other bone
metastases were not visualized, and there was no evidence
of a local tumor recurrence or new metastases. The acro-
mium had not been irradiated, and the increased sclerosis
was, therefore, considered likely to be an osteoblastic
healing response to erlotinib and she continued on treat-
ment. Three months later in January 2009, a MRI of the
vertebral column demonstrated a reduction in the size of
the (irradiated and nonirradiated) vertebral and sacral me-
tastases confirming a response to erlotinib. Unfortunately,
in April 2009, there was disease progression with an
increase in the size of an osteolytic cervical metastasis
with vertebral collapse and associated nerve root compres-
sion. She discontinued erlotinib, and palliative radiother-
apy was administered.
CASE HISTORY 2
In September 2007, a nonsmoking white male pre-
sented with stage IV (T2N3M1) adenocarcinoma of the left
lower lobe with multiple liver and pulmonary metastases.
In addition, an osteolytic lesion was seen in the 12th
thoracic vertebra on the diagnostic CT scan of the thorax
(Figure 2A), and a staging positron emission tomography
showed increased tracer uptake in the 6th cervical, 3rd
thoracic, and 12th thoracic vertebrae (the latter corre-
sponding to the osteolytic lesion seen on CT), sacroiliac
joints bilaterally, and left ischial tuberosity confirming
multiple bone metastases. Mutational analysis of the tumor
revealed an activating EGFR mutation (exon 19 deletion),
and he was started on erlotinib 150 mg once daily. The first
follow-up CT scan after 6 weeks showed osteoblastic
activity in the metastasis of the 12th thoracic vertebra and
a new osteoblastic lesion in the 3rd thoracic vertebra
FIGURE 1. Axial, contrast-en-
hanced computed tomography
(CT) image of the thorax before
erlotinib showed (A) an osteolytic
bone metastases in the right acro-
mium (arrow). (B) Three months
after starting erlotinib, increased
osteosclerosis was seen at the site
of this metastasis (arrow).
FIGURE 2. Axial, contrast-en-
hanced computed tomography
(CT) image of the thorax at the
time of diagnosis showed (A) an
osteolytic bone metastasis in the
12th thoracic vertebra (arrow). A
CT scan after 6 weeks of erlotinib
treatment showed (B) osteoblastic
activity in the metastasis of the
12th thoracic vertebra (arrow) and
(D) an osteoblastic lesion in the
third thoracic vertebra (arrow) not
visible at baseline (C).
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(Figures 2B–D) and a marked reduction in the size and
cavitation of the primary tumor, reduction of the medias-
tinal lymphadenopathy, reduction in size and number of
the pulmonary metastases, and disappearance of the liver
metastases. In view of the good response elsewhere, the
osteoblastic lesions were considered an osteoblastic re-
sponse to treatment and erlotinib was continued. Repeat
follow-up CT scans of the thorax showed persistent partial
response and a CT scan of the pelvis after 6 months
showed sclerotic lesions at the sites of known bone me-
tastases and new sites consistent with an osteoblastic
response. Nevertheless, in May 2008, there was progres-
sion of the primary tumor, and erlotinib treatment was
discontinued.
CASE HISTORY 3
In June 2006, a 46-year-old white never smoker
presented with stage IIIb (T4N1M0) adenocarcinoma of the
left upper lobe for which she received six cycles of
paclitaxel/carboplatin.14 In June 2007, she developed pro-
gressive disease with multiple mixed osteolytic and osteo-
blastic bone metastases in the thoracic and lumbar verte-
brae, and liver and brain metastases. In view of the clinical
characteristics predicting a good response, she started
erlotinib 150 mg once daily. This was discontinued after 7
days, because of a severe, grade 4 generalized papulopus-
tular rash. Subsequently, she completed six cycles of
gemcitabine/cisplatin and four cycles of pemetrexed. In
August 2008, a follow-up CT scan showed new intrapul-
monary and intracerebral metastases. In addition, the bone
metastases had become symptomatic, and the patient had
developed new painful osteolytic metastases in her ster-
num (Figures 3A and C). Because of the lack of other
alternatives, we again offered her erlotinib but at a reduced
dose (50 mg once daily). This was well tolerated with
toxicity limited to a grade 2 papulopustular rash. After 6
weeks of therapy, a CT scan showed a reduction in the size
and number of the intrapulmonary and liver metastases. A
CT scan 4 weeks later showed marked diffuse osteoblastic
activity in the metastases in the sternum and lumbar
vertebra and osteosclerosis surrounding the metastasis in
the thoracic vertebrae (Figures 3B and D). In view of the
persistent intrapulmonary and intraheptic response and
improvement in the bone pain, the increased osteosclerosis
was considered an osteoblastic treatment response. Mutational
analysis of a biopsy from a pleural metastasis demonstrated an
activating EGFR mutation (exon 21 L858R mutation). Erlotinib
was continued until May 2009 when there was progression of
the liver metastases.
DISCUSSION
We describe three patients receiving erlotinib for
NSCLC who develop osteoblastic bone lesions seen on CT
in the presence of otherwise ongoing treatment response
elsewhere. All had known bone metastases before starting
treatment. In two patients, these were osteolytic and in one
patient mixed osteolytic and osteoblastic. Although no
pathologic confirmation was obtained, the osteoblastic
lesions that developed during therapy were considered
likely to be an osteoblastic response reflecting bone repair
and treatment efficacy. This phenomenon is well docu-
mented for breast and prostrate cancers, but only a few
cases have been described for NSCLC.9–13 This is the first
report of osteoblastic response to erlotinib.
Erlotinib is an EGFR inhibitor that is approved for
patients with NSCLC who have failed at least one plati-
num-based chemotherapy regimen. The mechanism
whereby erlotinib may induce an osteoblastic response in
FIGURE 3. Axial, contrast-en-
hanced computed tomography
(CT) image of the thorax before
low-dose erlotinib showed (A) os-
teolytic bone metastases in the
sternum and thoracic vertebra (ar-
rows) and (B) mild osteoblastic ac-
tivity in the lumbar vertebra (ar-
row). A CT scan after 10 weeks of
erlotinib treatment showed (B)
marked osteoblastic activity in the
sternum (arrow), osteosclerosis
around the metastases in the tho-
racic vertebrae (arrow), and (D)
diffuse, increased osteosclerosis in
the lumbar vertebra.
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patients with bone metastases from NSCLC is unclear. It
has been hypothesized that EGFR inhibition induces os-
teoblastic proliferation and prevents osteoclast prolifera-
tion and activation. Osteoblastosis may thereby represent
an indirect sign of efficient EGFR blockade within bone
metastases.15
All our cases had tumors with an activating mutation
in the EGFR gene. Such mutations are associated with
response to EGFR inhibitors, as was demonstrated. In
addition, EGFR mutations have recently been found to be
associated with the Wnt/-catenin pathway in NSCLC.15
In prostate cancer, the Wnt/-catenin pathway is known to
be associated with osteoblastic bone metastases. The rela-
tionship among EGFR mutations, EGFR inhibitors, Wnt/
-catenin, and osteoblastosis in NSCLC warrants further
investigation.
With the increasing use of EGFR mutational analysis to
guide patient selection for erlotinib, response rates are expected
to improve, and it is, therefore, likely that more cases of
osteoblastic response will be seen. In addition, there are many
other tyrosine kinase inhibitors undergoing clinical investiga-
tion. These may similarly be associated with the development of
osteoblastic bone lesions, as those seen with gefinitib and erlo-
tinib. Therefore, it is important that physicians and radiologists
involved in the care of patients with NSCLC are aware of this
phenomenon. The appearance of osteoblastic bone lesions in the
setting of otherwise stable or responding disease should be
interpreted with caution because misinterpretation as disease
progression will lead to the premature cessation of effective
therapy.
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